Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Pre-ablation use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) did not reduce atrial fibrillation (AF) recurrence after ablation. This study found no significant difference in AF recurrence or adverse outcomes between GLP-1 RA users and nonusers post-ablation.
Area Of Science
- Cardiology
- Pharmacology
- Medical Informatics
Background
- The association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use before atrial fibrillation (AF) ablation and subsequent AF recurrence remains unclear.
- Understanding this relationship is crucial for optimizing AF management strategies.
Purpose Of The Study
- To investigate the impact of GLP-1 RA use within one year prior to AF ablation on AF recurrence.
- To assess the association between pre-ablation GLP-1 RA use and related adverse outcomes.
Main Methods
- Utilized the TriNetX research database to identify adult patients undergoing AF ablation between 2014 and 2023.
- Employed propensity score matching (1:1) to compare GLP-1 RA users and nonusers based on various clinical factors.
- Defined the primary outcome as a composite of cardioversion, new antiarrhythmic drug initiation, or repeat ablation, with secondary outcomes including stroke, hospitalization, and mortality.
Main Results
- The matched cohort included 1,625 GLP-1 RA users and 1,625 nonusers.
- Pre-ablation GLP-1 RA therapy showed no significant association with a reduced risk of AF recurrence (composite outcome: HR 1.04, 95% CI 0.92-1.19).
- No significant differences were observed in the rates of ischemic stroke, all-cause hospitalization, or mortality between the groups during the 12-month follow-up.
Conclusions
- Preprocedural use of GLP-1 RAs does not appear to decrease the risk of AF recurrence or associated adverse events after ablation.
- Further research is warranted to elucidate the potential role of GLP-1 RAs in improving outcomes for patients with AF.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...